期刊
HUMAN PATHOLOGY
卷 44, 期 10, 页码 2071-2074出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.humpath.2013.02.022
关键词
Melanoma; Melanogenesis; Melanin; Metastatic melanoma; Survival
类别
资金
- Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University [64/2009]
- National Institutes of Health [1R01AR056666-01A2, R01A1R052190]
Because melanogenesis can affect immune responses to and chemotherapy and radiotherapy for melanoma, we analyzed overall survival and disease-free survival times in melanoma patients in relation to the degree of tumor pigmentation. Clinicopathologic data were obtained from the Oncology Centre, Prof Franciszek Lukaszczyk Memorial Hospital, Bydgoszcz, Poland. The overall survival and disease-free survival analyses were performed using the log-rank test, whereas differences between mean/median overall survival and disease-free survival (days) were analyzed using the Student t test In patients with metastatic disease, those with melanotic melanomas exhibited significantly shorter disease-free survival and overall survival than those with amelanotic lesions. Similarly, melanin-producing lymph node metastases were linked to shorter overall survival and disease-free survival, which was confirmed by a significantly longer mean/median disease-free survival for amelanotic versus melanotic metastases. Melanogenesis shortens overall survival and disease-free survival in patients with metastatic melanoma. Inhibition of melanogenesis appears a rational adjuvant approach to the therapy of metastatic melanoma. (C 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据